<DOC>
	<DOCNO>NCT00915915</DOCNO>
	<brief_summary>Investigation two transdermal hormone patch formulation contraception regard inhibition ovulation period 3 treatment cycle healthy young female volunteer</brief_summary>
	<brief_title>Inhibition Ovulation Pharmacokinetics Transdermal Ethinylestradiol ( EE ) Gestodene ( GSD )</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Gestodene</mesh_term>
	<mesh_term>Femovan</mesh_term>
	<criteria>BMI : 18 BMI 30 kg/mÂ² Healthy female volunteer Age 1835 year ( smoker old 30 year , inclusive ) Ovulatory pretreatment cycle , least 3 month since delivery Abortion lactation first screen examination Willingness use nonhormonal method contraception entire study Contraindications use combine ( estrogen/gestodene ) contraceptive ( e.g . history venous/artial thromboembolic disease Regular intake medication OCs Clinically relevant finding ( blood pressure , physical gynaecological examination , laboratory examination ) anovulatory pretreatment cycle</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Female contraception</keyword>
	<keyword>Ovulation inhibition</keyword>
</DOC>